CD19 and graft versus host disease: Due to delayed recovery of adaptive immunity and associated infection risks, strategies for ex vivo elimination of αβ T cells and CD19 B cells with no pharmacologic prophylaxis for GVHD has been utilized for haploidentical transplant in patients with non-malignant disorders (13, 22).